8 Review of guidance

8.1 The guidance on this technology will be considered for review by the Guidance Executive alongside NICE technology appraisal guidanceĀ 199 ('Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis', review date June 2013). The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
April 2011

  • National Institute for Health and Care Excellence (NICE)